Current Diabetes Reports

, Volume 3, Issue 5, pp 378–385

Insulin therapy for type 2 diabetes

  • Afshin Sasali
  • Jack L. Leahy


Type 2 diabetes is a disease of insulin deficiency along with insulin resistance, and the natural history is a progressive worsening of insulin secretion over time. The obvious conclusion supported by clinical experience is most patients will eventually need insulin therapy. However, there is often a reluctance on the part of many care providers to prescribe insulin because of fears of weight gain, hypoglycemia, or cardiovascular consequences, or because the patient is unwilling. Another problem is many practitioners are uncertain how to use insulin in type 2 diabetes. This review discusses the benefits of insulin therapy in patients with type 2 diabetes when it is required for optimal glycemia control. It also debunks the fears over unwanted consequences such as severe hypoglycemia and worsening of atherosclerotic cardiovascular disease. Finally, it provides a ‘hands on‘ approach on how to start basal insulin therapy and multishot insulin therapy in type 2 diabetes.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001, 414:782–787.PubMedCrossRefGoogle Scholar
  2. 2.
    Economic costs of diabetes in the U.S. in 2002. American Diabetes Association [no authors listed]. Diabetes Care 2003, 26:917–932.CrossRefGoogle Scholar
  3. 3.
    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854–865.CrossRefGoogle Scholar
  4. 4.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–853.CrossRefGoogle Scholar
  5. 5.
    Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393. Important study showing that a comprehensive prevention program for cardiovascular disease in patients with type 2 diabetes based on aggressive pharmacologic intervention of glycemia, blood pressure, dyslipidemia, microalbuminuria, and aspirin use lowered cardiovascular disease nearly 50%.PubMedCrossRefGoogle Scholar
  6. 6.
    Clinical practice recommendations 2003. American Diabetes Association [no authors listed]. Diabetes Care 2003, 26(suppl 1):S1-S156.Google Scholar
  7. 7.
    Saaddine JB, Engelau MM, Beckles GL, et al.: A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002, 136:565–574.PubMedGoogle Scholar
  8. 8.
    Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360–372.PubMedCrossRefGoogle Scholar
  9. 9.
    Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002, 347:1342–1349. Well-discussed overview of the available therapies for type 2 diabetes.PubMedCrossRefGoogle Scholar
  10. 10.
    Riddle MC: Timely addition of insulin to oral therapy for type 2 diabetes. Diabetes Care 2002, 25:395–396.PubMedCrossRefGoogle Scholar
  11. 11.
    DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. Scientific review. JAMA 2003, 289:2254–2264.PubMedCrossRefGoogle Scholar
  12. 12.
    DeWitt DE, Dugdale DC: Using new insulin strategies in the outpatient treatment of diabetes. Clinical applications. JAMA 2003, 289:2265–2269.PubMedCrossRefGoogle Scholar
  13. 13.
    Chan JL, Abrahamson MJ: Pharmacologic management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc 2003, 78:459–467.PubMedCrossRefGoogle Scholar
  14. 14.
    Gerich JE: Novel insulins: expanding options in diabetes management. Am J Med 2002, 113:308–316. Comprehensive overview of available insulin preparations.PubMedCrossRefGoogle Scholar
  15. 15.
    Cohen FJ, Neslusan CA, Conklin JE, Song X: Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 2003, 26:1847–1851.PubMedCrossRefGoogle Scholar
  16. 16.
    Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002, 26(suppl 3):S18-S24.PubMedCrossRefGoogle Scholar
  17. 17.
    Weyer C, Bogardus C, Mott DM, et al.: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787–794.PubMedCrossRefGoogle Scholar
  18. 18.
    Butler AE, Janson J, Bonner-Weir S, et al.: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102–110. Study making the important observation that prediabetes is characterized by a reduction in à-cell mass.PubMedCrossRefGoogle Scholar
  19. 19.
    Overview of 6 years therapy of type 2 diabetes: a progressive disease (UKPDS 16). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Diabetes 1995, 44:1249–1258.CrossRefGoogle Scholar
  20. 20.
    Turner RC, Cull CA, Frighi V, et al.: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005–2012.PubMedCrossRefGoogle Scholar
  21. 21.
    Garvey WT, Olefsky JM, Griffin J, et al.: The effect of insulin treatment on insulin secretion and action in type 2 diabetes mellitus. Diabetes 1985, 34:222–234.PubMedCrossRefGoogle Scholar
  22. 22.
    Kosaka K, Kuzuya T, Akanuma Y, et al.: Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980, 18:23–28.PubMedCrossRefGoogle Scholar
  23. 23.
    Ilkova H, Glaser B, Tunckale A, et al.: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353–1356.PubMedCrossRefGoogle Scholar
  24. 24.
    Yale JF, Valiquett TR, Ghazzi MN, et al.: The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:737–745. Well-known study showing the limited benefit of adding a third oral agent to patients failing two oral agents.PubMedGoogle Scholar
  25. 25.
    Kiayias JA, Vlachou ED, Theodosopoulou E, et al.: Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care 2002, 25:1251–1252.PubMedCrossRefGoogle Scholar
  26. 26.
    Yki-Järvinen H, Ryysy L, Nikkila K, et al.: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999, 130:389–396.PubMedGoogle Scholar
  27. 27.
    Rosenstock J, Riddle M, Dailey G, et al.: Treatment to target study: Feasibility of achieving control with the addition of basal bedtime insulin glargine or NPH insulin in insulin-naive patients with type 2 diabetes on oral agents [abstract]. Diabetes 2001, 50(suppl 2):A129.Google Scholar
  28. 28.
    Abraira C, Colwell JA, Nuttall FQ, et al.: Veterans affairs cooperative study on glycemic control and complications in type 2 diabetes (VA CSDM). Diabetes Care 1995, 18:1113–1123.PubMedCrossRefGoogle Scholar
  29. 29.
    Avilés-Santa L, Sinding J, Raskin P: Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. Ann Intern Med 1999, 131:182–188.PubMedGoogle Scholar
  30. 30.
    Strowig SM, Avilés-Santa L, Raskin P: Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002, 25:1691–1698.PubMedCrossRefGoogle Scholar
  31. 31.
    Wulffelé MG, Kooy A, Lehert P, et al.: Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002, 25:2133–2140.PubMedCrossRefGoogle Scholar
  32. 32.
    Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 2003, 26:1902–1912.PubMedCrossRefGoogle Scholar
  33. 33.
    Harsch IA, Stocker S, Radespiel-Tröger M, et al.: Traffic hypoglycaemias and accidents in patients with diabetes mellitus treated with different antidiabetic regimens. J Intern Med 2002, 252:352–360.PubMedCrossRefGoogle Scholar
  34. 34.
    Yki-Järvinen H, Dressler A, Ziemen M: Less nocturnal hypoglycemia and better post-dinner control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000, 23:1130–1136.PubMedCrossRefGoogle Scholar
  35. 35.
    Rosenstock J, Schwartz SL, Clark CM, et al.: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine and NPH insulin. Diabetes Care 2001, 24:631–636.PubMedCrossRefGoogle Scholar
  36. 36.
    Fritsche A, Schweitzer MA, Häring H-U: Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003, 138:952–959.PubMedGoogle Scholar
  37. 37.
    White JR Jr, Campbell RK, Hirsch IB: Novel insulins and strict glycemic control. Analogues approximate normal insulin secretory response. Postgrad Med 2003, 113:30–36.PubMedGoogle Scholar
  38. 38.
    Després J-P, Lamarche B, Mauriége P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952–957.PubMedCrossRefGoogle Scholar
  39. 39.
    Malmberg K: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997, 314:1512–1515.PubMedGoogle Scholar
  40. 40.
    Malmberg K, Norhammar A, Wedel H, Rydén L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999, 99:2626–2632.PubMedGoogle Scholar
  41. 41.
    Dandona P, Aijada A, Bandyopadhay A: The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care 2003, 26:516–519.PubMedCrossRefGoogle Scholar
  42. 42.
    Henricsson M, Berntorp K, Fernlund P, Sundkvist G: Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care 2002, 25:381–385.PubMedCrossRefGoogle Scholar
  43. 43.
    Riddle MC, Hart JS, Bouma DJ, et al.: Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type 2 diabetes subjects. Diabetes Care 1989, 12:623–629.PubMedCrossRefGoogle Scholar
  44. 44.
    Riddle MC, Schneider J: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998, 21:1052–1057.PubMedCrossRefGoogle Scholar
  45. 45.
    Riddle MC, Rosenstock J: Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes. Successful control with less nocturnal hypoglycemia [abstract]. Diabetes 2002, 51(suppl 2):A113.Google Scholar
  46. 46.
    Yki-Järvinen: Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001, 24:758–767. Comprehensive overview of available data regarding the use of oral agents with insulin in type 2 diabetes.PubMedCrossRefGoogle Scholar
  47. 47.
    Wright A, Felix Burden AC, Paisey RB, et al.: Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330–336.PubMedCrossRefGoogle Scholar
  48. 48.
    Hollander PA, Levy P, Fineman MS, et al.: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 2003, 26:784–790.PubMedCrossRefGoogle Scholar
  49. 49.
    Cefalu WT: Evaluation of alternative strategies for optimizing glycemia: progress to date. Am J Med 2002, 113:23S-35S.PubMedCrossRefGoogle Scholar
  50. 50.
    Skyler JS, Cefalu WT, Kourides IA, et al.: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet 2001, 3357:331–335.CrossRefGoogle Scholar
  51. 51.
    Cefalu WT, Skyler JS, Kourides IA, et al.: Inhaled human insulin treatment in patients with type 2 diabetes. Ann Intern Med 2001, 134:203–207.PubMedGoogle Scholar
  52. 52.
    Zhang B, Salituro G, Szalkowski D, et al.: Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 289:2122–2125.Google Scholar
  53. 53.
    Air EL, Strowski MZ, Benoit SC, et al.: Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat Med 2002, 8:179–183.PubMedCrossRefGoogle Scholar
  54. 54.
    Kipnes M, Dandona P, Tripathy D, et al.: Control of postprandial glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 2003, 26:421–426.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Afshin Sasali
  • Jack L. Leahy
    • 1
  1. 1.Division of Endocrinology, Diabetes and Metabolism, and the Department of MedicineUniversity of Vermont College of MedicineBurlingtonUSA

Personalised recommendations